Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mallinckrodt Completes NDA Submission for Kidney Failure Drug

by Zacks Equity Research

Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.

Madeleine Johnson headshot

These 10 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Kinjel Shah headshot

Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infection

by Kinjel Shah

A U.S. based phase II/III study has been initiated to evaluate Regeneron (REGN)/Sanofi's (SNY) rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19.

Moderna Up as First Human Trial of Coronavirus Vaccine Begins

by Zacks Equity Research

Moderna (MRNA) announces dosing of first human in a phase I clinical study evaluating its coronavirus vaccine candidate. The National Institutes of Health is conducting the study.

Gilead Up as Remdesivir Shows Promise in Treating Coronavirus

by Zacks Equity Research

Gilead (GILD) leads the race of companies developing treatments for coronavirus with experimental candidate, remdesivir, showing promise.

Kinjel Shah headshot

4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy

by Kinjel Shah

Here we highlight four bigshot drugmakers/biotechs whose stocks are up this year in spite of the coronavirus impact.

J&J Signs Another Collaboration to Develop Coronavirus Vaccine

by Zacks Equity Research

J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.

The Zacks Analyst Blog Highlights: HENKY, NFLX, PTON, TDOC and GILD

by Zacks Equity Research

The Zacks Analyst Blog Highlights: HENKY, NFLX, PTON, TDOC and GILD

Agenus (AGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Agenus (AGEN) betters loss estimates and also beats on sales in the fourth quarter. The company gets a Fast Track tag for balstilimab & zalifrelimab combo to address the second-line cervical cancer.

Kinjel Shah headshot

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

by Kinjel Shah

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Roche's (RHHBY) Coronavirus Test Achieves EUA From the FDA

by Zacks Equity Research

Roche's (RHHBY) cobas SARS-CoV-2 Test for the qualitative detection of SARS-CoV-2, the virus that causes the COVID-19 disease, gets EUA from the FDA.

Ekta Bagri headshot

Biotech Sector in Focus as Coronavirus Spreads Panic

by Ekta Bagri

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Urmimala Biswas headshot

4 Sectors in Focus Following Coronavirus-Induced Selloff

by Urmimala Biswas

While COVID-19 has dealt a huge blow to most sectors, it has opened up enormous opportunities for a few.

Kinjel Shah headshot

3 Small Biotechs Provide Coronavirus Drug Development Updates

by Kinjel Shah

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

New Strong Sell Stocks for March 12th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Gilead (GILD) Announces Positive Long-Term Results on Descovy

by Zacks Equity Research

Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.

Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment

by Zacks Equity Research

Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

Regeneron (REGN) Gains from Focus on Coronavirus Treatments

by Zacks Equity Research

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for combating the novel coronavirus.

Why Is Gilead (GILD) Up 15.4% Since Last Earnings Report?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus

by Zacks Equity Research

Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.

Inovio Surges on Expedited Timeline for Coronavirus Vaccine

by Zacks Equity Research

Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.

Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More

by Zacks Equity Research

The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.

Are Options Traders Betting on a Big Move in Gilead (GILD) Stock?

by Zacks Equity Research

Investors need to pay close attention to Gilead (GILD) stock based on the movements in the options market lately.

Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B

by Zacks Equity Research

Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.